Thymogen — Research, Dosing & Price Guide

Thymogen (Glu-Trp) is a synthetic dipeptide bioregulator designed to mimic the immunomodulatory activity of thymic peptides. Developed at the Russian Institute of Bioregulation and Gerontology, it is used clinically in Russia as an immunostimulant for treating immunodeficiency states, chronic infections, and as an adjunct in post-surgical recovery. It represents the simplest active thymic peptide fragment.

Thymogen's dipeptide sequence (glutamic acid-tryptophan) is proposed to interact with immune cell receptors and gene regulatory elements to modulate T-cell maturation and function. It enhances the differentiation of T-cell progenitors in the thymus, increases the ratio of CD4+ helper T cells, and normalizes the CD4/CD8 ratio in immunocompromised states. Thymogen also modulates cytokine production — it enhances IL-2 and interferon-gamma production by Th1 cells while suppressing excessive Th2 cytokine responses, promoting balanced immune function rather than simple stimulation. At the molecular level, the Glu-Trp dipeptide is thought to interact with transcription factors involved in T-cell gene expression, including those regulating TCR signaling components.

• Russian clinical trials demonstrated improved immune parameters (CD4/CD8 ratio, total T-cell count) in patients with secondary immunodeficiency
• Thymogen showed efficacy as an adjunctive therapy for chronic respiratory infections, reducing relapse rates
• Studies in post-surgical patients showed faster immune recovery and reduced infection rates with thymogen administration
• Khavinson et al. documented thymogen's ability to normalize dysregulated immune function in elderly patients
• Animal studies showed thymogen enhanced survival and immune function in immunosuppressed models

• Russian clinical protocol: 100 mcg intramuscularly or subcutaneously daily for 3–10 days
• Intranasal form: 25 mcg per nostril, 1–2 times daily for 10 days
• Oral supplementation: available as capsules at 10–25 mg daily for 10–30 days
• Repeat courses every 1–3 months as needed for chronic immunodeficiency
• Often used prophylactically during cold/flu season: 10-day courses monthly
• Can be combined with other thymic peptides for comprehensive immune support

Known Side Effects

• Generally very well tolerated with minimal side effects
• Rare: mild allergic reactions at the injection site
• Transient low-grade fever (sign of immune activation) in some patients
• No significant adverse effects reported in clinical use in Russia

Safety Profile

Thymogen has been approved and used clinically in Russia for over 20 years with an excellent safety record. As a dipeptide, it has negligible immunogenicity and toxicity. It does not suppress immune function — it modulates and normalizes it, making it theoretically safer than broad immunosuppressants or stimulants. However, caution is advised in autoimmune conditions where T-cell stimulation could exacerbate disease. Western clinical trial data is limited. Not recommended in patients with organ transplants on immunosuppressive therapy. No known drug interactions.

Day 1–3: No obvious effects. Immune modulation is occurring at the cellular level. Day 3–7: Subtle improvement in overall vitality. Patients with active infections may notice slightly faster resolution. Day 7–10: Course is typically completed. Immune parameters (if measured) show improvement in T-cell counts and ratios. Post-course: Benefits persist for 1–3 months. Users often report fewer colds, faster recovery from illness, and improved general resistance to infection. Repeat courses extend and reinforce these effects.

Prices sourced from peptides.gg marketplace. Prices may vary.